Therapies targeting estrogen receptor (ER) are being widely used to treat ER+ breast cancer patients. Despite early detection and improved survival outcomes, tamoxifen resistance, either intrinsic or acquired- is a major obstacle in effective disease management. Current review will summarize different molecular mechanisms of tamoxifen resistance both intrinsic and acquired in breast cancer treatment. This review not only provides basis to understand the nature of tamoxifen drug resistance but also suggests the mechanisms for its control leading to improved therapeutic interventions
Approximately 70% of breast cancers express the estrogen receptor (ER) and endocrine therapy is the ...
Seventy five percent of all breast cancer (BC) patients express estrogen receptor (ER) but a quarter...
Seventy five percent of all breast cancer (BC) patients express estrogen receptor (ER) but a quarter...
17β-Estradiol (E2) plays a pivotal role in the development and progression of breast cancer. As a re...
17β-Estradiol (E2) plays a pivotal role in the development and progression of breast cancer. As a re...
17β-Estradiol (E2) plays a pivotal role in the development and progression of breast cancer. As a re...
17β-Estradiol (E2) plays a pivotal role in the development and progression of breast cancer. As a re...
Endocrine therapy, the first targeted therapy in oncology, is the most successful systemic therapy i...
Endocrine therapy, the first targeted therapy in oncology, is the most successful systemic therapy i...
Endocrine therapy, the first targeted therapy in oncology, is the most successful systemic therapy i...
Breast cancer is the most frequent malignancy diagnosed in women. Approximately 70% of breast tumors...
Tamoxifen is the drug most used for early breast cancer treatment in oestrogen receptor (ER) positiv...
Tamoxifen has been the mainstay of hormonal therapy in both early and advanced breast cancer patient...
Tamoxifen has been the mainstay of hormonal therapy in both early and advanced breast cancer patient...
Tamoxifen has been the mainstay of hormonal therapy in both early and advanced breast cancer patient...
Approximately 70% of breast cancers express the estrogen receptor (ER) and endocrine therapy is the ...
Seventy five percent of all breast cancer (BC) patients express estrogen receptor (ER) but a quarter...
Seventy five percent of all breast cancer (BC) patients express estrogen receptor (ER) but a quarter...
17β-Estradiol (E2) plays a pivotal role in the development and progression of breast cancer. As a re...
17β-Estradiol (E2) plays a pivotal role in the development and progression of breast cancer. As a re...
17β-Estradiol (E2) plays a pivotal role in the development and progression of breast cancer. As a re...
17β-Estradiol (E2) plays a pivotal role in the development and progression of breast cancer. As a re...
Endocrine therapy, the first targeted therapy in oncology, is the most successful systemic therapy i...
Endocrine therapy, the first targeted therapy in oncology, is the most successful systemic therapy i...
Endocrine therapy, the first targeted therapy in oncology, is the most successful systemic therapy i...
Breast cancer is the most frequent malignancy diagnosed in women. Approximately 70% of breast tumors...
Tamoxifen is the drug most used for early breast cancer treatment in oestrogen receptor (ER) positiv...
Tamoxifen has been the mainstay of hormonal therapy in both early and advanced breast cancer patient...
Tamoxifen has been the mainstay of hormonal therapy in both early and advanced breast cancer patient...
Tamoxifen has been the mainstay of hormonal therapy in both early and advanced breast cancer patient...
Approximately 70% of breast cancers express the estrogen receptor (ER) and endocrine therapy is the ...
Seventy five percent of all breast cancer (BC) patients express estrogen receptor (ER) but a quarter...
Seventy five percent of all breast cancer (BC) patients express estrogen receptor (ER) but a quarter...